G. Varuni Kondagunta , Guru Sonpavde , Matthew D. Galsky , Mark T. Fleming , Thomas E. Hutson , Cora N. Sternberg
{"title":"Novel treatment options for refractory germ cell tumors","authors":"G. Varuni Kondagunta , Guru Sonpavde , Matthew D. Galsky , Mark T. Fleming , Thomas E. Hutson , Cora N. Sternberg","doi":"10.1016/j.uct.2008.10.001","DOIUrl":null,"url":null,"abstract":"<div><p>Although testicular germ cell tumors (GCTs) are a model for a curable neoplasm, a significant proportion will relapse and require salvage therapy. While currently available conventional and high-dose chemotherapy salvage regimens attain durable complete remissions in a significant proportion of patients, the long-term outcomes are still suboptimal in this young population. Several novel agents are being evaluated for recurrent germ cell tumors, including chemotherapeutic and biologic agents, notably anti-angiogenic agents. A better understanding of biology may lead to enhanced outcomes for cisplatin-refractory patients with germ cell tumors.</p></div>","PeriodicalId":87487,"journal":{"name":"Update on cancer therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2008-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.uct.2008.10.001","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Update on cancer therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1872115X08000170","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Although testicular germ cell tumors (GCTs) are a model for a curable neoplasm, a significant proportion will relapse and require salvage therapy. While currently available conventional and high-dose chemotherapy salvage regimens attain durable complete remissions in a significant proportion of patients, the long-term outcomes are still suboptimal in this young population. Several novel agents are being evaluated for recurrent germ cell tumors, including chemotherapeutic and biologic agents, notably anti-angiogenic agents. A better understanding of biology may lead to enhanced outcomes for cisplatin-refractory patients with germ cell tumors.